Agathe Sanson-Edet

Rouen, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Automatic lesion segmentation in ⁶⁸Ga-PSMA PET/CT and ¹⁷⁷Lu-PSMA SPECT/CT: added value of PET-guided SPECT in a bicentric study.

Automatic lesion segmentation in ⁶⁸Ga-PSMA PET/CT and ¹⁷⁷Lu-PSMA SPECT/CT: added value of PET-guided SPECT in a bicentric study.

Journal: EJNMMI research

Published: January 15, 2026

Clinical value of per-treatment whole-body single-time-point automated dosimetry for [177Lu]Lu-PSMA-617 therapy in metastatic castration-resistant prostate cancer.

Clinical value of per-treatment whole-body single-time-point automated dosimetry for [177Lu]Lu-PSMA-617 therapy in metastatic castration-resistant prostate cancer.

Journal: European journal of nuclear medicine and molecular imaging

Published: November 24, 2025

GMP-compliant automated synthesis and quality control of [177Lu]Lu-PSMA-I&T using the GAIA/LUNA Elysia-Raytest module for the treatment of metastatic castration-resistant prostate cancer.

GMP-compliant automated synthesis and quality control of [177Lu]Lu-PSMA-I&T using the GAIA/LUNA Elysia-Raytest module for the treatment of metastatic castration-resistant prostate cancer.

Journal: EJNMMI radiopharmacy and chemistry

Published: September 01, 2025

[123I]-mIBG and [18F]-FDOPA differential uptake in the follow-up of neonatal neuroblastoma.

[123I]-mIBG and [18F]-FDOPA differential uptake in the follow-up of neonatal neuroblastoma.

Journal: EJNMMI reports

Published: June 25, 2025

Title Not Found

Title Not Found

Journal: Bulletin du cancer

Published: November 06, 2024

177 Lu-PSMA-617 Radioligand Therapy in Patient With Prostate Cancer Sciatic Nerve Metastasis.

177 Lu-PSMA-617 Radioligand Therapy in Patient With Prostate Cancer Sciatic Nerve Metastasis.

Journal: Clinical nuclear medicine

Published: October 28, 2024

Towards fully automatized [177Lu]Lu-PSMA personalized dosimetry based on 360° CZT whole-body SPECT/CT: a proof-of-concept.

Towards fully automatized [177Lu]Lu-PSMA personalized dosimetry based on 360° CZT whole-body SPECT/CT: a proof-of-concept.

Journal: EJNMMI physics

Published: October 02, 2024

Dosimetry for targeted radionuclide therapy in routine clinical practice: experts advice vs. clinical evidence.

Dosimetry for targeted radionuclide therapy in routine clinical practice: experts advice vs. clinical evidence.

Journal: European journal of nuclear medicine and molecular imaging

Published: December 19, 2023

Using 18F-FDG-PET/CT Metrics to Predict Survival in Ra-Dio-Iodine Refractory Thyroid Cancers.

Using 18F-FDG-PET/CT Metrics to Predict Survival in Ra-Dio-Iodine Refractory Thyroid Cancers.

Journal: Diagnostics (Basel, Switzerland)

Published: August 26, 2022

Severe carcinoid syndrome revealing a primary ovarian carcinoid tumor.

Severe carcinoid syndrome revealing a primary ovarian carcinoid tumor.

Journal: Bulletin du cancer

Published: October 27, 2020

Respiratory gated multistatic PET reconstructions to delineate radiotherapy target volume in patients with mobile lung tumors.

Respiratory gated multistatic PET reconstructions to delineate radiotherapy target volume in patients with mobile lung tumors.

Journal: The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...

Published: January 11, 2020

Impact of the Bayesian penalized likelihood algorithm (Q.Clear®) in comparison with the OSEM reconstruction on low contrast PET hypoxic images.

Impact of the Bayesian penalized likelihood algorithm (Q.Clear®) in comparison with the OSEM reconstruction on low contrast PET hypoxic images.

Journal: EJNMMI physics

Published: October 22, 2019

Showing 1-12 of 27

Last Updated: 09/26/2026